Skip to content
lifestyle.nextmentors.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
FibroBiologics, Inc.
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 4, 2026
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
April 30, 2026
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
April 30, 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements
April 28, 2026
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
March 5, 2026
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026
←
Previous Page
1
2
3